Renal Function
Conditions
Brief summary
This study is designed to observe the effect of renal function on the pharmacokinetic, safety, and tolerability profiles of Ulipristal acetate following administration of a single oral dose of a 10 mg Ulipristal acetate tablet.
Interventions
DRUGUlipristal acetate
Sponsors
Allergan
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
for Patients with Renal Impairment: * Have a negative result from a serum pregnancy test at screening and a negative result from a serum or urine pregnancy test on Day -1 * If premenopausal, have regular menstrual cycles (cycles of 24-35 days duration) over the past 6 months as reported by the patient * If female of childbearing potential, agree to use an effective method of contraception (i.e., condom plus diaphragm with spermicide, condom with spermicide, or nonhormonal intrauterine device) and not become pregnant throughout the study. Subjects who are at least 2-years postmenopausal (with supporting documentation from an obstetrician/gynecologist) or who have had tubal ligation or hysterectomy will not be considered to be of childbearing potential * Be nonsmoking (never smoked or have not smoked within the previous 6 months) or a light smoker (fewer than 10 cigarettes per day within the previous 3 months) * For Patients with Renal Impairment, have medical history, physical examination, laboratory, and other test results consistent with their degree of renal impairment, as determined by the Investigator * For Patients with Normal Renal Function, have a state of general good health based on medical history and routine physical examination and are matched to the age and weight of the renal dysfunction patients (mean group difference ±10 years for age and \< 20% for weight)
Exclusion criteria
* Known hypersensitivity to Ulipristal Acetate (UPA) or other selective progesterone receptor modulators * For Patients with Renal Impairment, clinically significant disease state, in the opinion of the examining physician, in any body system (other than renal function impairment) * For Patients with Normal Renal Function, clinically significant disease state, in the opinion of the examining physician, in any body system * Positive test results for anti-human immunodeficiency virus type 1, hepatitis B surface antigen, or anti-hepatitis C virus at screening * Abnormal and clinically significant results on physical examination, medical history, serum chemistry, hematology, or urinalysis * History of alcohol or other substance abuse within the previous 5 years * Positive test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, alcohol, cannabinoids, opiates, or phencyclidine at screening or Day -1. Patients with Renal Impairment many be enrolled if the positive test result is due to prescription drug use and approved by the Principal Investigator and Sponsor Study Physician, on a case-by-case basis * Participation in any other clinical investigation using an experimental drug requiring repeated blood or plasma draws within 30 days of IP administration * Participation in a blood or plasma donation program within 60 or 30 days, respectively, of Investigational Product (IP) administration * Previously participated in an investigational study of Ulipristal Acetate * Breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the plasma concentration versus time curve of ulipristal acetate from time 0 to time t (AUC 0-t) | Day 1 (0 hour) to Day 8 (168 hours) |
| Maximum plasma drug concentration (Cmax) of ulipristal acetate | Day 1 (0 hour) to Day 8 (168 hours) |
| Time of maximum plasma drug concentration (Tmax) of ulipristal acetate | Day 1 (0 hour) to Day 8 (168 hours) |
| Terminal elimination half-life (T½) of ulipristal acetate | Day 1 (0 hour) to Day 8 (168 hours) |
| Apparent total body clearance of ulipristal acetate from plasma after extravascular administration (CL/F) of ulipristal acetate | Day 1 (0 hour) to Day 8 (168 hours) |
| Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of ulipristal acetate | Day 1 (0 hour) to Day 8 (168 hours) |
| Area under the plasma concentration versus time curve of ulipristal acetate from time 0 to infinity (AUC 0-∞) | Day 1 (0 hour) to Day 8 (168 hours) |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative amount of PGL4002 excreted into urine from time zero to time t (Ae0-t) | Day 1 (0 hour) to Day 8 (168 hours) |
| Area under the plasma concentration versus time curve of PGL4002 (ulipristal acetate active metabolite) from time 0 to time t (AUC 0-t) | Day 1 (0 hour) to Day 8 (168 hours) |
| Area under the plasma concentration versus time curve of PGL4002 (ulipristal acetate active metabolite) from time 0 to infinity (AUC 0-∞) | Day 1 (0 hour) to Day 8 (168 hours) |
| Renal clearance of PGL4002 from plasma (CLR) | Day 1 (0 hour) to Day 8 (168 hours) |
| Time of maximum plasma drug concentration (Tmax) of PGL4002 (ulipristal acetate active metabolite) | Day 1 (0 hour) to Day 8 (168 hours) |
| Terminal elimination half-life (T½) of PGL4002 (ulipristal acetate active metabolite) | Day 1 (0 hour) to Day 8 (168 hours) |
| Maximum plasma drug concentration (Cmax) of PGL4002 (ulipristal acetate active metabolite) | Day 1 (0 hour) to Day 8 (168 hours) |
| Cumulative amount of ulipristal acetate excreted into urine from time zero to time t (Ae0-t) | Day 1 (0 hour) to Day 8 (168 hours) |
| Renal clearance of ulipristal acetate from plasma (CLR) | Day 1 (0 hour) to Day 8 (168 hours) |
| Percent of dose excreted as unchanged ulipristal acetate in urine (%Dose) | Day 1 (0 hour) to Day 8 (168 hours) |
Countries
United States
Outcome results
None listed